Microbion and Haisco Announce Equity Investment and Development & Commercialization Agreement for MBN-101 in China and Related Territories

BOZEMAN, MT and VANCOUVER, BC--(Marketwired - March 01, 2016) - Microbion
Corporation ("Microbion") of Bozeman, MT, USA and Microbion Pharma Corp. of
Vancouver, BC, Canada, today announced that Microbion has entered into an
agreement with Haisco Pharmaceutical Group ("Haisco") to develop and
commercialize its lead clinical stage compound, MBN-101, for wounds in China and
related territories. MBN-101 is the first in a new class of products to treat
infections by attacking both bacteria and related biofilms. Haisco, a leading
pharmaceutical manufacturer in China, will be responsible for development,
regulatory, and commercialization costs for MBN-101 in China, and Microbion and
Haisco will share profits from the commercialization of MBN-101 in China. Haisco
is also making an equity investment in Microbion Corporation at the signing of
this agreement. 
"We are very pleased to be working with Haisco on developing MBN-101 for China,"
said Karim Lalji, Chairman & CEO of Microbion Pharma Corp. "This partnership
ensures that MBN-101 will be developed and commercialized in China to benefit
patients suffering from infected wounds, including chronic wound infections such
as those associated with diabetic foot ulcers. This agreement enables Microbion
to continue the development of MBN-101 in North America, Europe and other
markets. Microbion welcomes Haisco as a sophisticated and knowledgeable investor
and partner." 
"Haisco is excited to have the opportunity to develop and commercialize MBN-101
for chronic wounds in China. China has one of the highest prevalence rates of
diabetes in the world and Haisco believes that MBN-101, a first in class,
innovative therapy, could make a significant difference in improving the lives
of patients," said Mr. Junmin Wang, Chairman & CEO of Haisco.
About Chronic Wounds

Chronic wounds are wounds which have failed to heal effectively and in a timely
manner. Chronic wounds affect approximately six million patients in the United
States on an annual basis. The most common risk factors for developing chronic
wounds include diabetes, vascular disease, and obesity. Bacterial infection and
biofilm are considered one of the main causes of impaired healing in chronic
wounds. The most common chronic wound types are diabetic foot ulcers, venous leg
ulcers and pressure ulcers. Chronic wounds represent a significant burden to
patients, health care professionals and the U.S. health care system, costing an
estimated $25 billion dollars annually. There are over 70,000 amputations
annually on diabetic patients and 80% of diabetic amputations are preceded by an
ulcer. There are over 100,000 hospitalizations in the U.S. annually for diabetic
foot ulcers. 
About Microbion Corporation
Microbion is a clinical stage biopharmaceutical company. Microbion is developing
MBN-101 as the first product in the bismuth-thiol class for the treatment of
resistant and difficult to treat infections. MBN-101 has broad spectrum,
anti-bacterial efficacy against a broad range of pathogens, including multiple
priority pathogens or "superbugs". In addition to anti-bacterial efficacy,
MBN-101 also has the ability to eradicate biofilms. The dual action from this
first in class product provides a novel clinical approach to treating
infections. Microbion filed an IND in the United States for MBN-101 in 2015. The
company initiated its first Phase 2a study in 2016. MBN-101 has been granted
Qualified Infectious Disease Product (QIDP) designation by the FDA for
orthopedic device-related infections and was also granted Fast Track status for
this indication by the FDA in 2015. 
About Haisco Pharmaceutical Group
Haisco Pharmaceutical Group, founded in 2000, is a publicly listed company
focusing on marketing and sales of internally-developed therapeutic drugs.
Haisco is one of the leading companies in China's pharmaceutical industry. The
company's products are sold to more than 3,000 hospitals throughout China with
annual hospital terminal sales of over US $800 million.
Safe Harbor Statement
Certain of the statements made in this press release are forward looking, such
as those, among others, relating to the success of clinical development of
MBN-101 and preparation for potential commercialization. These statements are
subject to risks and uncertainties that could cause actual results and events to
differ materially from those anticipated, including, but not limited to, risks
and uncertainties related to: our ability to enroll patients in our clinical
trials at the pace that we project; the size and growth of the potential markets
for MBN-101 or any future product candidates and our ability to serve those
markets; our ability to obtain and maintain regulatory approval of MBN-101 or
any future product candidates; and our expectations regarding the potential
safety, efficacy or clinical utility of MBN-101 or any future product
candidates. Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Microbion Corporation
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Karim Lalji

Chairman & CE0

Microbion Pharma Corp.

Email: [email protected]

Phone: (406) 522-7393

(406) 522-7393